Question 1

What is Cadonilimab?

Accepted Answer

Cadonilimab is a Other.

Question 2

How often does Cadonilimab appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 33 articles.

Question 3

When was Cadonilimab first tracked by Ergen?

Accepted Answer

First tracked on May 25, 2026.

Question 4

When was Cadonilimab last mentioned in news?

Accepted Answer

Last active on Jun 08, 2026.

Question 5

What is Cadonilimab's current news sentiment?

Accepted Answer

Aggregate sentiment score: 65 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Cadonilimab in global news coverage?

Accepted Answer

Attention score of 7, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Cadonilimab?

Accepted Answer

ASCO 2026 Oncology Research Presentations (May 25, 2026, 33 articles).

Question 8

How did the "ASCO 2026 Oncology Research Presentations" event impact Cadonilimab?

Accepted Answer

Cadonilimab is another core first-in-class bispecific antibody from Akeso's portfolio, with regimens being presented for various tumor types at ASCO 2026, indicating its potential clinical benefits.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.